All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-10-02T20:49:28.000Z

Once-weekly dosing of carfilzomib approved by FDA

Oct 2, 2018
Share:

Bookmark this article

The US Food and Drug Administration (FDA) has approved a once-weekly dosing regimen of carfilzomib (Kyprolis®) in combination with dexamethasone, to treat patients with relapsed and refractory multiple myeloma (MM). The new indication enables a single 70 mg/m2 dose to be administered once-weekly (along with dexamethasone), instead of the previous twice-weekly dose of 27 mg/m2.

The approval was based on the ARROW study presented at ASCO in June 2018, and previously detailed in an interview for the MM Hub by Maria Victoria Mateos. The study showed an improved PFS in patients receiving the once-weekly regimen and in addition, offers a more convenient regimen.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox